A popular corticosteroid inhaler used to treat asthma and other conditions is being discontinued, and despite generic versions now available, health experts are warning patients to plan ahead for ...

GSK’s perpetual asthma inhaler updates have kept generics makers chasing a moving target for more than half a century, and it’s patients who are being forced to foot the bill, a new lawsuit filed in a ...

One of the most widely-used asthma and breathing treatments for over 20 years is being taken off the shelves in 2024, potentially leaving patients, healthcare providers and insurers scrambling.

Missouri resident Elliot Conrad Dale recently filed an antitrust lawsuit against GlaxoSmithKline (“GSK”), claiming GSK employed a “device hopping” scheme to ensure uninterrupted patent and regulatory ...

LONDON, Aug. 20, 2014 /PRNewswire/ -- GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta ® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ARNUITY ELLIPTA contains the active ingredient fluticasone furoate.

Fluticasone furoate 50mcg, 100mcg, 200mcg; per inhalation; dry pwd for oral inhalation. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist for acute symptoms; monitor for ...